Integrum announced that the company entered a commercial collaboration and distribution agreement with Hanger. Within the framework of the agreement, Integrum’s prosthetic product portfolio will be made available to patients at Hanger Clinic’s 900 patient care facilities and distributed to other facilities. The agreement took effect on June 10.
“We see an immense value in collaborating with the industry leader in the US, who has the capabilities to promote our groundbreaking innovation directly to almost one-third of all amputees receiving orthotic and prosthetic care in the US, as well as distributing our products through the major distributor in the field, SPS. Through this agreement, we are convinced that the use of our technology will widen rapidly and gain further traction as a paradigm-shifting treatment alternative and become standard care,” said Rickard Brånemark, CEO of Integrum.
